Yang Song recently conducted research on WuXi AppTec and released a research report "Optimistic about the company's industrial and competitive landscape advantages, the US bill is expected to have limited substantive impact", this report gives WuXi AppTec a ** rating, and the current stock price is 5373 yuan.
WuXi AppTec (603259).
Summary of the event. On February 18, the company issued an announcement in response to the letter sent by the U.S. congressman to the U.S. ** on February 12, and the company strongly opposes the misleading allegations, inaccurate determinations and prejudgments without due process against the company; The company has always welcomed the supervision of its industry by regulators, and the company has successfully passed the US** review many times in the past; The Company strongly believes that it has not, is and will not pose a significant risk to the United States, and that the United States will come to the same conclusion if the Company is reviewed again. Investment Essentials.
The U.S. trade association warns the U.S. on behalf of its member companies about the bill**.
According to BioCentury's February 8, the Biotechnology Innovation Organization (BIO) in the United States has responded to the Act (S3558，h.r.7085) warned the United States that the anti-China biotechnology bills recently introduced in the House and Senate, if passed without amendment, would cause serious harm to the U.S. biotechnology industry and patients who rely on it to develop drugs, and cause incalculable damage to the currently approved and marketed drug development ** chain and drugs under development.
All the repurchased shares will be cancelled and the registered capital will be reduced, which fully demonstrates the confidence in future development.
The Company will complete RMB 1 billion of A shares and 12 H shares by February 5, 2024 and January 15, 2024, respectivelyThe HK$8.8 billion repurchase will be cancelled and the registered capital will be reduced, which will help boost the company's intrinsic value and fully demonstrate the company's confidence in future development.
The company continues to lead the global frontier of new pharmaceutical technologies, and its performance has maintained rapid growth.
The company continues to lead the global biotechnology frontier, and the world's first TIL cell **AMTA**I? The company will provide clinical development and manufacturing services, and the company will provide commercial manufacturing** for the Lovance plant until it is completed. The company reaffirmed at the JPM conference that it will achieve 2-3% growth in apparent revenue in 2023, with a 25-26% growth rate in regular business revenue excluding COVID-19 commercial projects, and an adjusted non-IFRS net profit growth rate of 41.7-42.1%, adjusted non-IFRS net profit is expected to exceed $10 billion for the first time, and free cash flow is expected to exceed $4.5 billion in 2023.
Profitability**: Affected by large order revenue and industry demand, we adjusted the company's operating income for 2023-2025 to 40506/449.36/531.2.4 billion yuan (originally 418. in 2023-2025.)12/514.93/654.7.1 billion yuan); The net profit attributable to the parent company was 10168/113.03/136.4.1 billion yuan (originally 97. in 2023-2025.)79/121.12/157.64), maintaining the "** rating." Risk warning: the number and growth of orders are less than expected, the release of production capacity is less than expected, the impact of exchange rate fluctuations on performance, the risk of fluctuation of investment income, and the risk of loss of core personnel.
*Star Data Center calculates according to the research report data released in the past three years, and the research team of CITIC ** Han Shitong has conducted in-depth research on the stock, and the average accuracy of the ** in the past three years is as high as 986%, and its **2023 attributable net profit is 1014.3 billion, **PE converted according to the current price is 1509。
The latest profit** breakdown is as follows:
A total of 14 institutions have rated the stock in the last 90 days, **14 ratings; The average institutional price target over the last 90 days is 8834。
The above content is compiled by **Star based on public information, generated by algorithms, and has nothing to do with the position of this site. **Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of the information (including but not limited to text, **audio, data and charts), if there is any problem, please contact us. This article is a compilation of data and does not constitute any investment advice for you.